Table 3.
Treatment-related AE of any grade occurring in ≥ 10% of patients and grade 3 treatment-related AEs occurring in ≥ 1 patient in cohort 3
| Treatment-related AEsan(%) | Cohort 3 N = 31 |
|
|---|---|---|
| Any grade | Grade 3 | |
| Any | 24 (77.4) | 6 (19.4) |
| Fatigue | 8 (25.8) | 0 |
| Pruritus | 7 (22.6) | 0 |
| Pneumonitis | 4 (12.9) | 0 |
| Bile duct obstruction | 1 (3.2) | 1 (3.2) |
| Colitis | 1 (3.2) | 1 (3.2) |
| Dehydration | 1 (3.2) | 1 (3.2) |
| Diffuse uveal melanocytic proliferation | 1 (3.2) | 1 (3.2) |
| Hyponatremia | 1 (3.2) | 1 (3.2) |
| Neutropenia | 1 (3.2) | 1 (3.2) |
| Rash | 1 (3.2) | 1 (3.2) |
AE adverse event
aAttribution of AEs to study treatment was determined by the investigator